ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
IssuerBlackrock
ETF TickerBTEE(USD) LSE
ETF TickerBTEE.L(GBP) LSE

Holdings detail for BCYC

Stock NameBicycle Therapeutics Ltd
TickerBCYC(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS0887861088

Show aggregate BCYC holdings

News associated with BCYC

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of “Moderate Buy” from Analysts
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average […] - 2025-07-29 02:14:55
Principal Financial Group Inc. Grows Stake in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC)
Principal Financial Group Inc. lifted its holdings in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Free Report) by 55.3% in the first quarter, Holdings Channel reports. The firm owned 631,260 shares of the company’s stock after buying an additional 224,790 shares during the period. Principal Financial Group Inc.’s holdings in Bicycle Therapeutics were worth $5,359,000 […] - 2025-07-17 04:35:03
Analyzing Bicycle Therapeutics (NASDAQ:BCYC) & Galecto (NASDAQ:GLTO)
Galecto (NASDAQ:GLTO – Get Free Report) and Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends. Profitability This table compares Galecto and Bicycle Therapeutics’ […] - 2025-07-15 06:24:40
Kevin Lee Sells 3,193 Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Stock
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Get Free Report) CEO Kevin Lee sold 3,193 shares of the company’s stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $7.44, for a total transaction of $23,755.92. Following the transaction, the chief executive officer owned 480,804 shares in the […] - 2025-07-09 07:17:05
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives $25.00 Consensus PT from Analysts
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average […] - 2025-07-07 02:32:44
Bicycle Therapeutics plc (NASDAQ:BCYC) Stock Holdings Raised by Harbor Capital Advisors Inc.
Harbor Capital Advisors Inc. raised its stake in Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) by 12.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 148,129 shares of the company’s stock after purchasing an additional 16,624 shares during the period. Harbor Capital Advisors Inc.’s holdings in Bicycle […] - 2025-06-13 05:18:56
Bicycle Therapeutics plc (NASDAQ:BCYC) Receives $25.00 Consensus Price Target from Analysts
Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) has been given an average rating of “Moderate Buy” by the ten research firms that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 […] - 2025-06-12 02:29:00
Deutsche Bank AG Sells 1,653 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)
Deutsche Bank AG cut its stake in Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) by 20.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,417 shares of the company’s stock after selling 1,653 shares during the period. Deutsche Bank […] - 2025-06-04 04:54:43
Bicycle Therapeutics plc (NASDAQ:BCYC) Given Average Rating of “Moderate Buy” by Analysts
Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective […] - 2025-05-15 02:52:49
Legal & General Group Plc Decreases Stake in Bicycle Therapeutics plc (NASDAQ:BCYC)
Legal & General Group Plc lessened its position in Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) by 41.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 139,075 shares of the company’s stock after selling 99,741 shares during the period. Legal & General Group Plc’s holdings in Bicycle Therapeutics were worth $1,947,000 at the […] - 2025-04-25 05:13:07
Renaissance Technologies LLC Decreases Position in Bicycle Therapeutics plc (NASDAQ:BCYC)
Renaissance Technologies LLC cut its stake in shares of Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) by 1.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 269,500 shares of the company’s stock after selling 3,100 shares during the quarter. Renaissance Technologies LLC’s holdings […] - 2025-04-23 05:27:02
Bicycle Therapeutics plc (NASDAQ:BCYC) Receives $29.14 Consensus PT from Brokerages
Shares of Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price […] - 2025-04-23 02:30:48
Needham & Company LLC Reaffirms “Buy” Rating for Bicycle Therapeutics (NASDAQ:BCYC)
Needham & Company LLC reiterated their buy rating on shares of Bicycle Therapeutics (NASDAQ:BCYC – Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $30.00 price objective on the stock. BCYC has been the subject of several other reports. Stephens reissued an “equal weight” rating and […] - 2025-03-12 04:58:43

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) BCYC holdings

DateNumber of BCYC Shares HeldBase Market Value of BCYC SharesLocal Market Value of BCYC SharesChange in BCYC Shares HeldChange in BCYC Base ValueCurrent Price per BCYC Share HeldPrevious Price per BCYC Share Held
2026-02-09 (Monday)35,274USD 203,884USD 203,884
2026-02-06 (Friday)35,197BCYC holding increased by 77USD 199,215BCYC holding decreased by -28714USD 199,21577USD -28,714 USD 5.66 USD 6.49001
2026-02-02 (Monday)35,120USD 227,929BCYC holding increased by 2459USD 227,9290USD 2,459 USD 6.49001 USD 6.41999
2026-01-30 (Friday)35,120BCYC holding increased by 154USD 225,470BCYC holding decreased by -2508USD 225,470154USD -2,508 USD 6.41999 USD 6.51999
2026-01-29 (Thursday)34,966BCYC holding increased by 77USD 227,978BCYC holding decreased by -18687USD 227,97877USD -18,687 USD 6.51999 USD 7.06999
2026-01-27 (Tuesday)34,889BCYC holding increased by 78USD 246,665BCYC holding increased by 2988USD 246,66578USD 2,988 USD 7.06999 USD 7
2026-01-26 (Monday)34,811USD 243,677BCYC holding increased by 1741USD 243,6770USD 1,741 USD 7 USD 6.94999
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of BCYC by Blackrock for IE00BDZVHG35

Show aggregate share trades of BCYC

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2026-02-06BUY77 5.660* -
2026-01-30BUY1546.5606.220 6.254USD 963 -
2026-01-29BUY776.7806.500 6.528USD 503 -
2026-01-27BUY787.1806.940 6.964USD 543 -
2026-01-23BUY1567.2706.910 6.946USD 1,084 -
2026-01-22BUY787.3246.910 6.951USD 542 -
2026-01-15BUY1606.6406.370 6.397USD 1,024 -
2026-01-14BUY1606.6506.420 6.443USD 1,031 -
2026-01-12BUY1606.8756.370 6.420USD 1,027 -
2026-01-09BUY2406.8006.580 6.602USD 1,584 -
2026-01-07BUY1607.0006.540 6.586USD 1,054 -
2026-01-02BUY807.1896.620 6.677USD 534 -
2025-12-30BUY806.8606.750 6.761USD 541 -
2025-12-23SELL-9727.1406.900 6.924USD -6,730 -
2025-12-17SELL-4057.5006.750 6.825USD -2,764 -
2025-12-16SELL-817.4057.100 7.130USD -578 -
2025-12-15BUY1627.4907.170 7.202USD 1,167 -
2025-12-11BUY1627.6507.300 7.335USD 1,188 -
2025-12-04BUY1,6207.2706.960 6.991USD 11,325 -
2025-12-02BUY1,2157.0906.835 6.861USD 8,336 -
2025-11-28BUY817.8307.270 7.326USD 593 -
2025-11-26BUY2437.3606.760 6.820USD 1,657 -
2025-11-26BUY2437.3606.760 6.820USD 1,657 -
2025-11-25BUY4056.9606.710 6.735USD 2,728 -
2025-11-24BUY816.7906.300 6.349USD 514 -
2025-11-20SELL-3246.7506.060 6.129USD -1,986 -
2025-11-19BUY816.6806.180 6.230USD 505 -
2025-11-18BUY4866.5506.170 6.208USD 3,017 -
2025-11-17BUY1626.6706.300 6.337USD 1,027 -
2025-11-14BUY816.7506.430 6.462USD 523 -
2025-11-12BUY806.8806.465 6.507USD 521 -
2025-11-10BUY806.6306.340 6.369USD 510 -
2025-11-06BUY806.6006.230 6.267USD 501 -
2025-11-04BUY807.3356.850 6.898USD 552 -
2025-10-30BUY4009.0807.990 8.099USD 3,240 -
2025-10-29BUY1608.1808.750 8.693USD 1,391 -
2025-10-22SELL-3167.8808.420 8.366USD -2,644 -
2025-10-20BUY1588.1608.390 8.367USD 1,322 -
2025-10-17BUY3948.1708.730 8.674USD 3,418 -
2025-10-15BUY6248.3908.500 8.489USD 5,297 -
2025-10-03BUY5608.3708.680 8.649USD 4,843 -
2025-10-02BUY808.5308.690 8.674USD 694 -
2025-09-30BUY1627.7407.830 7.821USD 1,267 -
2025-09-26BUY1627.4007.530 7.517USD 1,218 -
2025-09-25BUY1627.5407.780 7.756USD 1,256 -
2025-09-18BUY817.1607.230 7.223USD 585 -
2025-09-17BUY2436.9207.210 7.181USD 1,745 -
2025-07-17SELL-1588.0408.180 8.166USD -1,290 -
2025-07-11SELL-6408.0008.120 8.108USD -5,189 -
2025-07-02BUY4,4007.4407.737 7.707USD 33,912 -
2025-06-25BUY1607.1007.430 7.397USD 1,184 -
2025-06-11BUY1608.7609.360 9.300USD 1,488 -
2025-06-10BUY1608.6408.960 8.928USD 1,428 -
2025-06-04SELL-808.4608.460 8.460USD -677 -
2025-04-23BUY808.6709.520 9.435USD 755 -
2025-04-10SELL-6406.5306.815 6.787USD -4,343 -
2025-04-08SELL-806.3807.280 7.190USD -575 -
2025-04-07SELL-806.7507.085 7.052USD -564 -
2025-04-04SELL-4056.8907.410 7.358USD -2,980 -
2025-04-01BUY2,9797.8508.420 8.363USD 24,913 -
2025-03-31SELL-2168.4908.900 8.859USD -1,914 -
2025-03-14SELL-1,1529.69010.320 10.257USD -11,816 -
2025-03-07SELL-14410.23010.890 10.824USD -1,559 -
2025-03-04SELL-7210.14010.670 10.617USD -764 -
2025-02-25BUY14411.10011.480 11.442USD 1,648 -
2025-02-19SELL-7112.27012.397 12.384USD -879 -
2025-02-13BUY21312.49012.660 12.643USD 2,693 -
2025-02-12BUY7112.32012.450 12.437USD 883 -
2025-02-11BUY28411.64011.870 11.847USD 3,365 -
2024-12-30BUY1,28614.13014.875 14.801USD 19,033 -
2024-11-18SELL-96020.46022.180 22.008USD -21,128 -
2024-11-08SELL-6424.96025.280 25.248USD -1,616 -
2024-10-21SELL-6426.70027.255 27.199USD -1,741 -
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of BCYC

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1926,387087,23830.2%
2025-09-1816,3190141,60911.5%
2025-09-1712,243069,26617.7%
2025-09-1613,3720117,49111.4%
2025-09-1525,73910073,98534.8%
2025-09-1229,5200155,86118.9%
2025-09-1144,0920156,84328.1%
2025-09-1036,245096,66037.5%
2025-09-0916,517080,85620.4%
2025-09-0826,75215074,30436.0%
2025-09-058,223054,95015.0%
2025-09-0423,5330100,97123.3%
2025-09-039,971056,31617.7%
2025-09-0215,920062,93725.3%
2025-08-2953,1250144,35036.8%
2025-08-2810,028051,17419.6%
2025-08-2722,088062,53735.3%
2025-08-2619,969062,72631.8%
2025-08-2522,466080,68227.8%
2025-08-2218,441077,09223.9%
2025-08-216,031067,7618.9%
2025-08-2014,315063,38222.6%
2025-08-1924,38125467,90135.9%
2025-08-1847,1600118,00140.0%
2025-08-1524,405078,26231.2%
2025-08-1436,6800202,16818.1%
2025-08-1374,00131259,61728.5%
2025-08-1226,8960102,38226.3%
2025-08-1115,761065,78324.0%
2025-08-0866,9160127,61652.4%
2025-08-0719,839044,35244.7%
2025-08-0621,165071,99129.4%
2025-08-0520,479071,05628.8%
2025-08-0415,909051,91230.6%
2025-08-0114,179038,07337.2%
2025-07-3121,8550110,10819.8%
2025-07-3018,7551968,70827.3%
2025-07-2928,399145209,63813.5%
2025-07-2829,378078,99637.2%
2025-07-2520,752073,81828.1%
2025-07-2417,151073,85023.2%
2025-07-2339,2660137,33028.6%
2025-07-2222,7210193,78911.7%
2025-07-2128,8370135,60421.3%
2025-07-1845,3930263,43517.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy